NASDAQ$CCRN

Cross Country Healthcare Inc · Q2 2023 earnings

Q2 2023 earnings · · Investor relations

Briefing

Cross Country Healthcare's Q2 2023 financial results were announced, revealing a decrease in revenue and net income, but exceeding guidance ranges.

Cross Country Healthcare reported a decrease in revenue of 28% year-over-year and 13% sequentially, with a net income attributable to common stockholders of $21.3 million. However, the company's revenue and adjusted EPS exceeded guidance ranges, driven by strong growth in Physician Staffing and increased travel demand throughout the quarter. The company also repaid its term loan and repurchased shares.

  • Revenue and Adjusted EPS exceeded guidance ranges.
  • Physician Staffing reported strong revenue growth of 105% year-over-year and 12% sequentially.
  • Travel demand increased throughout the quarter
  • Strong quarterly operating cash flows of $119 million

Headline financials

Total Revenue

$541M

Previous: $754M-28.2%
EPS (adj)

$0.69

Previous: $1.40-50.7%
Nurse/Allied FTEs

11.4K

No prior period
Physician Days Filled

23.8K

No prior period
Rev per Day Filled

$1.9K

Previous: $1.78K+6.8%
Capital Expenditures

-$7.67M

Previous: -$3.85M-99.4%
Free Cash Flow

$13.7M

Previous: $49M-72.1%
Net Income

$21.3M

Previous: $52.9M-59.6%
Operating Income

$35.2M

Previous: $78.8M-55.4%
Gross Profit

-$418M

Previous: -$583M+28.4%
Cash & Equivalents

$673K

Previous: $279K+141.2%
Total Assets

$771M

Previous: $939M-17.9%
Stock-Based Comp

$2.21M

Previous: $2.11M+4.3%

Revenue & EPS history

Cross Country Healthcare · Revenue · Quarterly

$541M

Q2 2023-28.2%vs Q2 2022
Beat estimate in 11 of 15 quarters(73%)
ActualEstimate

Revenue by segment

Cross Country Healthcare · $541M total across 2 segments · Q2 2023

  • Nurse and Allied Staffing
    $495M-32.3%
  • Physician Staffing
    $45.3M+104.9%

Forward guidance

The company provided guidance for the third quarter of 2023, expecting revenue between $440 million and $450 million, adjusted EBITDA between $27.0 million and $32.0 million, and adjusted EPS between $0.35 and $0.45. The company updated its 2023 annual minimum guidance to at least $2.05 billion in revenue and a full year Adjusted EBITDA margin of approximately 8%.

Historical earnings impact

How earnings announcements have historically affected this stock's price.

Avg. return before/after earnings

Based on 20 quarterly earnings reports · overlaid with Q2 2023

Historical avgQ2 2023

-2.7%

Avg return

Earnings day

-1.5%

Avg return

5 days after

+0.5%

Avg return

30 days after

44%

28 / 64 earnings

Positive

+24.6%

Q3 2021

Best reaction

-33.6%

Q2 2010

Worst reaction

Earnings price reactions
QuarterReport dateReaction (Day 0)+5 days+30 days
Q1 2026+0.8%+0.4%+0.8%
Q4 2025+8.2%+7.9%+0.5%
Q3 2025-14.1%-7.2%-32.9%
Q1 2025+0.4%+0.8%-6.7%
Q4 2024+0.3%-6.0%-13.9%
Q3 2024+7.2%-6.1%+57.9%
Q2 2024-2.7%-8.2%-17.3%
Q1 2024-4.9%-9.0%-14.1%
Q4 2023-2.7%-0.3%+5.7%
Q3 2023-14.0%-19.0%-10.7%
Q2 2023-14.7%-14.0%-3.8%
Q1 2023+5.1%+9.9%+26.1%
Q4 2022-5.6%+3.2%-13.2%
Q3 2022-2.5%-11.3%-2.8%
Q2 2022-13.7%-14.1%-7.6%
Q1 2022-2.6%-7.1%+0.9%
Q4 2021-1.5%+6.6%+2.4%
Q3 2021+24.6%+18.0%+21.1%
Q2 2021+23.0%+14.6%+29.7%
Q1 2021+16.5%+24.0%+17.4%
Q4 2020+18.9%+24.6%+33.8%
Q3 2020-5.0%-3.0%+9.3%
Q2 2020+9.6%+4.7%+1.6%
Q1 2020-4.8%-2.0%+7.6%
Q4 2019+0.4%-12.2%-27.7%
Q3 2019+14.2%+16.9%+10.9%
Q2 2019-0.8%-5.5%+5.6%
Q1 2019+4.7%+18.7%+0.9%
Q4 2018-3.6%-11.6%-22.5%
Q3 2018+7.8%+3.4%+2.7%
Q2 2018-30.9%-26.0%-14.7%
Q1 2018-16.7%-11.0%-4.3%
Q4 2017-18.8%-13.6%-15.8%
Q3 2017-9.6%-13.8%-2.6%
Q2 2017+3.1%+1.2%+2.5%
Q1 2017-13.0%-15.1%-16.7%
Q4 2016+3.4%-5.3%-7.2%
Q3 2016+22.9%+24.3%+31.7%
Q2 2016-11.5%-17.0%-14.2%
Q1 2016+10.0%
Q4 2015-21.9%
Q3 2015+9.5%
Q2 2015+10.1%
Q1 2015-4.6%
Q4 2014-9.6%
Q3 2014-0.5%
Q2 2014+1.8%
Q1 2014-14.3%
Q4 2013-22.3%
Q3 2013+3.1%
Q2 2013-3.3%
Q1 2013+0.4%
Q4 2009-5.5%
Q3 2012-0.9%
Q2 2012-5.5%
Q1 2011-3.1%
Q1 2012+11.8%
Q4 2011+0.8%
Q3 2010+2.5%
Q3 2011+2.5%
Q2 2011-33.6%
Q4 2010-33.6%
Q2 2010-33.6%
Q1 2010-7.9%

Discussion

Share your read of this quarter. Sign-in carries your eToro identity.

Join the conversation

Sign in with eToro to post your read of this quarter and vote on others'.

Sign in with eToro